Merck & Co., Inc. is understood to be closing in on an $11bn deal to acquire Acceleron but pharma sector watchers are not ruling out a late bid from rival firms notably Bristol Myers Squibb.
A report from the Wall Street Journal on Monday identified Merck as the frontrunner in the race to acquire the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?